Medication info
Subast Tablet 20 Milligrams (Rosuvastatin Calcium)

Subast Tablet 20 Milligrams (Rosuvastatin Calcium)

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›20.8mg / 1 tablet
Manufacturer / importer
Hanmi Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated tablets
Packaging
30 tablets/box [15 tablets/PTP/X2], 300 tablets/bottle
Approval status
Active

MFDS item code 201000983 · Approved 2010.01.28 · Insurance code 643505440

Summary

Main use
Improvement of dyslipidemia, reduction of cardiovascular disease risk, and inhibition of atherosclerosis progression
Who takes it
Adults · Children
Adult dose
Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which is adequate for most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or more according to LDL cholesterol levels, the treatment goal, and the patient's response, and may be increased up to a maximum of 20 mg daily. Elderly patients No dose adjustment is necessary. Patients with renal impairment No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. Patients with hepatic impairment No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but exposure was increased in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. Race Since systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients.
Child dose
Aged 10 to 17 years: The usual dosage range is 5 mg to 20 mg once daily. (There are no clinical data on doses higher than 20 mg in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. Dose adjustments should be made at intervals of 4 weeks or more. Safety and efficacy have not been established in children younger than 10 years.

Ingredients

Manufacturer
Hanmi Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of dyslipidemia, reduction of cardiovascular disease risk, and inhibition of atherosclerosis progression

  • Primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • dyslipidemia
  • primary dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is primarily used as an adjunct in patients with primary hypercholesterolemia and mixed dyslipidemia when dietary control and exercise are insufficient. It is also used together with dietary methods or other treatments in patients with homozygous familial hypercholesterolemia to assist in cholesterol management. It lowers total cholesterol and LDL cholesterol levels in patients with hypercholesterolemia, effectively delaying the progression of atherosclerosis. It is used as an adjunct to diet in children with heterozygous familial hypercholesterolemia who meet specific criteria. It also assists patients with primary dysbetalipoproteinemia and is effective in reducing the risk of stroke, myocardial infarction, and arterial revascularization in middle-aged patients at high risk for cardiovascular diseases. This medication is used for hyperlipidemia and reducing the risk of cardiovascular diseases.

How to take

Adult dose

Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which is adequate for most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or more according to LDL cholesterol levels, the treatment goal, and the patient's response, and may be increased up to a maximum of 20 mg daily. Elderly patients No dose adjustment is necessary. Patients with renal impairment No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. Patients with hepatic impairment No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but exposure was increased in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. Race Since systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients.

Child dose

Aged 10 to 17 years: The usual dosage range is 5 mg to 20 mg once daily. (There are no clinical data on doses higher than 20 mg in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. Dose adjustments should be made at intervals of 4 weeks or more. Safety and efficacy have not been established in children younger than 10 years.

Precautions

This medication should not be administered to certain patients. For example, it must not be used in patients who have allergies to any of its components, those with severely impaired liver function, patients with muscle diseases, and those with severely impaired kidney function. Women who are pregnant or nursing, as well as women of childbearing age who are not using appropriate contraception, must consult a physician before using this medication, and potential risks to the fetus must be adequately considered. Patients at high risk for muscle-related side effects, such as those with moderate or severe kidney impairment, hypothyroidism, a family history of muscle diseases, or those taking certain medications, should avoid high doses of this medication. Additionally, this medication contains lactose, so patients with lactose intolerance should not use it. Patients with poor liver function or those consuming excessive alcohol should undergo regular liver function tests while using this medication, and patients with hypercholesterolemia due to hypothyroidism or nephrotic syndrome should start this medication after treating the underlying condition. If symptoms like muscle pain, weakness, or cramps occur, they should inform a doctor immediately, and blood tests should be conducted to check for muscle damage. If symptoms are severe or blood test results are unfavorable, discontinuation of the medication may be necessary. Rarely, severe skin reactions, liver damage, neurological abnormalities, or muscle rupture may occur with this medication, so patients should consult medical personnel immediately if any unusual symptoms arise. This medication may interact with other drugs, so patients taking other medications should inform their doctor or pharmacist, especially if taking certain antivirals, immunosuppressants, or fibrate medications. Pregnant or nursing women should not use this medication, and women of childbearing age should use appropriate contraceptive methods. In cases of overdose, there is no specific antidote, and treatment should be symptomatic, with regular monitoring of liver function and muscle enzyme levels. Dizziness may occur while taking this medication, so patients should exercise caution when driving or operating machinery.

Side effects

Hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, memory loss, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, extraocular muscle weakness, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms syndrome, morbilliform drug rash, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, numbness, paraesthesia, chest discomfort, loss of appetite, abdominal distension, syncope, generalized pain, fatigue

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it must be stored in a tightly sealed container. It is advisable to maintain the storage temperature between 1 and 30 degrees Celsius at room temperature. Doing so will help ensure the medication's effectiveness is safely maintained for a long period of time.

Appearance and packaging

Appearance

Pink round film-coated tablets

Package unit

30 tablets/box [15 tablets/PTP/X2], 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.